LT3076971T - Kompozicijos ir būdai, skirti sumažinti didžiąsias širdies ir kraujagyslių komplikacijas - Google Patents

Kompozicijos ir būdai, skirti sumažinti didžiąsias širdies ir kraujagyslių komplikacijas

Info

Publication number
LT3076971T
LT3076971T LTEPPCT/US2014/068527T LT14068527T LT3076971T LT 3076971 T LT3076971 T LT 3076971T LT 14068527 T LT14068527 T LT 14068527T LT 3076971 T LT3076971 T LT 3076971T
Authority
LT
Lithuania
Prior art keywords
compositions
methods
cardiovascular complications
major cardiovascular
reducing major
Prior art date
Application number
LTEPPCT/US2014/068527T
Other languages
English (en)
Inventor
Preston KLASSEN
Kristin Taylor
Original Assignee
Nalpropion Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52575014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3076971(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nalpropion Pharmaceuticals Llc filed Critical Nalpropion Pharmaceuticals Llc
Publication of LT3076971T publication Critical patent/LT3076971T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
LTEPPCT/US2014/068527T 2013-12-06 2014-12-04 Kompozicijos ir būdai, skirti sumažinti didžiąsias širdies ir kraujagyslių komplikacijas LT3076971T (lt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361913216P 2013-12-06 2013-12-06
US201361914938P 2013-12-11 2013-12-11
US201461984580P 2014-04-25 2014-04-25
US14/322,810 US8969371B1 (en) 2013-12-06 2014-07-02 Compositions and methods for weight loss in at risk patient populations
PCT/US2014/068527 WO2015085044A1 (en) 2013-12-06 2014-12-04 Compositions and methods for reducing major adverse cardiovascular events

Publications (1)

Publication Number Publication Date
LT3076971T true LT3076971T (lt) 2022-02-10

Family

ID=52575014

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2014/068527T LT3076971T (lt) 2013-12-06 2014-12-04 Kompozicijos ir būdai, skirti sumažinti didžiąsias širdies ir kraujagyslių komplikacijas

Country Status (34)

Country Link
US (9) US8969371B1 (lt)
EP (2) EP4005571A1 (lt)
JP (2) JP6665094B2 (lt)
KR (3) KR102472432B1 (lt)
CN (3) CN117159547A (lt)
AU (1) AU2014360492A1 (lt)
BR (1) BR112016012755A2 (lt)
CA (1) CA2932127C (lt)
CL (1) CL2016001362A1 (lt)
CR (1) CR20160313A (lt)
CY (1) CY1125114T1 (lt)
DK (1) DK3076971T3 (lt)
EA (1) EA201690964A1 (lt)
EC (1) ECSP16057765A (lt)
ES (1) ES2903391T3 (lt)
HR (1) HRP20220058T1 (lt)
HU (1) HUE057551T2 (lt)
IL (3) IL300870A (lt)
JO (1) JOP20140344B1 (lt)
LT (1) LT3076971T (lt)
MX (2) MX389742B (lt)
PE (1) PE20161034A1 (lt)
PL (1) PL3076971T3 (lt)
PT (1) PT3076971T (lt)
PY (1) PY1454647A (lt)
RS (1) RS62846B1 (lt)
RU (1) RU2711638C2 (lt)
SG (1) SG10201808055QA (lt)
SI (1) SI3076971T1 (lt)
TN (1) TN2016000231A1 (lt)
TW (1) TWI661826B (lt)
UY (1) UY35864A (lt)
WO (1) WO2015085044A1 (lt)
ZA (1) ZA201603831B (lt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2350327C2 (ru) 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Составы, вызывающие потерю веса
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
CA2668885C (en) 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
EP3659604A1 (en) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
PT3730132T (pt) * 2012-06-06 2022-08-16 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
KR20180135012A (ko) 2016-04-28 2018-12-19 노보 노르디스크 에이/에스 심혈관 병태에서의 세마글루타이드
WO2018027815A1 (zh) * 2016-08-11 2018-02-15 华为技术有限公司 基于非授权频谱的无线通信方法、基站和终端设备
EP4444417A4 (en) * 2021-12-09 2026-02-11 Incarda Therapeutics Inc INHALATED THERAPY FOR CARDIAC ARRHYTHMIA
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217353A (en) 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
IL58649A (en) 1978-11-10 1982-04-30 Beecham Group Ltd Pharmaceutical dispensing container
JPS59500418A (ja) 1982-03-16 1984-03-15 ザ　ロツクフエラ−　ユニバ−シテイ 胃腸能動作用障害を回復する方法
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
PH23901A (en) 1987-05-04 1989-12-18 Lilly Co Eli Treatment of diabetes using fluoxetine
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5403595A (en) 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
DE4136215A1 (de) 1991-11-02 1993-05-06 Ferring Arzneimittel Gmbh, 2300 Kiel, De Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
DK0782445T3 (da) 1994-09-19 2002-05-06 Bristol Myers Squibb Pharma Co Kombination af en opioidantagonist og en selektiv serotoningenoptagelsesinhibitor til behandling af alkoholisme og alkoholafhængighed
US5627187A (en) 1995-04-12 1997-05-06 Katz; Bruce E. 5-FU for treating actinic kerotoses
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5716976A (en) 1996-03-13 1998-02-10 Bernstein; Richard K. Method of treatment for carbohydrate addiction
CA2220768A1 (en) 1996-03-13 1997-09-18 Yale University Smoking cessation treatments using naltrexone and related compounds
EP0795327A1 (en) 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
DE69736928T2 (de) 1996-05-07 2007-06-28 Pliva Istrazivanje I Razvoj D.O.O. Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus
EP0915697B1 (en) 1996-06-28 2002-09-18 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant sulfamate derivatives useful in treating obesity
US5878750A (en) 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
AU750808B2 (en) 1997-10-03 2002-07-25 Cary Medical Corporation Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
US6262049B1 (en) 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
EP1051167A1 (en) 1998-01-29 2000-11-15 Sepracor, Inc. Pharmaceutical uses of optically pure (-) -bupropion
US6048322A (en) 1998-04-15 2000-04-11 Kushida; Clete Morphometric measurement tool
US6210716B1 (en) 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US6589553B2 (en) 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
US6071918A (en) 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US6489350B1 (en) 1999-09-15 2002-12-03 Elan Pharmaceuticals, Inc. Methods for treating neuropathic pain using heteroarylmethanesulfonamides
US6403657B1 (en) 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20020055512A1 (en) 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
CA2397726A1 (en) 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
WO2001052851A1 (en) 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
EP2517710B1 (en) 2000-02-08 2015-03-25 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US6306436B1 (en) 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
PT1326630E (pt) 2000-09-18 2008-09-02 Sanos Bioscience As Utilização de péptidos glp-2
WO2002100382A2 (en) 2001-06-08 2002-12-19 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
WO2003013479A1 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Compositions and methods to prevent abuse of opioids
MXPA04001210A (es) 2001-08-06 2004-07-08 Euro Celtique Sa Formulaciones de agonista opioide con antagonista liberable y aislado.
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030087896A1 (en) 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20040102440A1 (en) 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
US20040029941A1 (en) 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
CN101310723A (zh) 2002-05-17 2008-11-26 迪欧加药品公司 有效的选择性阿片受体调制剂化合物的用途
JP4545584B2 (ja) 2002-05-17 2010-09-15 デューク ユニバーシティ 肥満を治療するための方法
US20040005368A1 (en) 2002-07-01 2004-01-08 Morris Mann Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite
US6972291B2 (en) 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
US7086532B2 (en) 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
AU2003283958A1 (en) 2002-09-13 2004-04-30 Elan Pharmaceuticals, Inc. Method of treating tremors
US20040192715A1 (en) 2003-02-05 2004-09-30 Mark Chasin Methods of administering opioid antagonists and compositions thereof
US20040204472A1 (en) 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
EP1613324A2 (en) 2003-04-14 2006-01-11 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
RU2350327C2 (ru) 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Составы, вызывающие потерю веса
EP1633400A2 (en) 2003-05-16 2006-03-15 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
US20070099884A1 (en) 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
CA2539027C (en) 2003-09-25 2010-02-23 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20070149451A1 (en) 2003-11-17 2007-06-28 Holmes David G Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
US7429580B2 (en) 2004-01-13 2008-09-30 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US20050245541A1 (en) 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
BRPI0510593A (pt) 2004-05-03 2007-11-20 Univ Duke composições para afetar a perda de peso
US20050250838A1 (en) 2004-05-04 2005-11-10 Challapalli Prasad V Formulation for sustained delivery
JP2008509142A (ja) 2004-08-03 2008-03-27 オレキシジェン・セラピューティクス・インコーポレーテッド 体重減少に影響を及ぼすためのブプロピオンと第２の化合物との組合せ
WO2007047351A2 (en) 2005-10-13 2007-04-26 Orexigen Therapeutics, Inc. Methods for treating hypertension in overweight and obese individuals
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
TW200803901A (en) 2005-11-28 2008-01-16 Orexigen Therapeutics Inc Methods of treating anxiety disorders
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
ES2749800T3 (es) 2006-06-05 2020-03-23 Nalpropion Pharmaceuticals Llc Formulación de liberación sostenida de naltrexona
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP2719378B1 (en) 2006-06-19 2016-08-31 Alpharma Pharmaceuticals LLC Pharmaceutical compositions
CA2693992C (en) 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US8682445B2 (en) 2006-07-28 2014-03-25 Cyberonics, Inc. Patient management system for treating depression using an implantable medical device
CA2668885C (en) 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
TW201811315A (zh) 2006-11-09 2018-04-01 美商歐瑞根治療有限公司 層狀醫藥調配物
GB2447949B (en) 2007-03-29 2010-03-31 Renasci Consultancy Ltd A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
EP2303025A4 (en) * 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
EP3659604A1 (en) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
US20130252995A1 (en) 2010-12-03 2013-09-26 Orexigen Therapeutics, Inc. Methods for reducing binge or compulsive eating
PT3730132T (pt) 2012-06-06 2022-08-16 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Also Published As

Publication number Publication date
CY1125114T1 (el) 2023-06-09
MX2022001251A (es) 2022-02-23
JP2020037593A (ja) 2020-03-12
ZA201603831B (en) 2023-05-31
CR20160313A (es) 2018-01-26
SI3076971T1 (sl) 2022-04-29
PT3076971T (pt) 2022-01-26
SG10201808055QA (en) 2018-10-30
WO2015085044A1 (en) 2015-06-11
CN114404419A (zh) 2022-04-29
US20210069181A1 (en) 2021-03-11
PL3076971T3 (pl) 2022-04-04
CN105899210A (zh) 2016-08-24
TN2016000231A1 (en) 2017-10-06
KR20220165791A (ko) 2022-12-15
US20150366860A1 (en) 2015-12-24
CA2932127A1 (en) 2015-06-11
EP3076971B1 (en) 2021-10-20
KR102472432B1 (ko) 2022-11-30
US20190374535A1 (en) 2019-12-12
US20160310485A1 (en) 2016-10-27
ES2903391T3 (es) 2022-04-01
AU2014360492A1 (en) 2016-06-23
CL2016001362A1 (es) 2017-01-06
ECSP16057765A (es) 2017-02-24
DK3076971T3 (da) 2022-01-24
HRP20220058T1 (hr) 2022-04-15
US10835527B2 (en) 2020-11-17
US9119850B2 (en) 2015-09-01
KR20230152800A (ko) 2023-11-03
HUE057551T2 (hu) 2022-05-28
UY35864A (es) 2015-07-31
US8969371B1 (en) 2015-03-03
NZ720620A (en) 2022-03-25
MX389742B (es) 2025-03-20
EA201690964A1 (ru) 2016-12-30
US20180243288A1 (en) 2018-08-30
US10231962B2 (en) 2019-03-19
PE20161034A1 (es) 2016-11-13
CN117159547A (zh) 2023-12-05
JP7204634B2 (ja) 2023-01-16
PY1454647A (es) 2017-10-02
BR112016012755A2 (pt) 2017-08-08
US10231964B2 (en) 2019-03-19
US20250144089A1 (en) 2025-05-08
JP6665094B2 (ja) 2020-03-13
TWI661826B (zh) 2019-06-11
US10828294B2 (en) 2020-11-10
TW201607536A (zh) 2016-03-01
JP2016539164A (ja) 2016-12-15
MX2016007231A (es) 2016-08-04
US11998542B2 (en) 2024-06-04
CA2932127C (en) 2023-05-02
EP4005571A1 (en) 2022-06-01
EP3076971A4 (en) 2017-06-28
IL282117A (en) 2021-05-31
JOP20140344B1 (ar) 2021-08-17
IL245919A0 (en) 2016-07-31
RS62846B1 (sr) 2022-02-28
KR20160095076A (ko) 2016-08-10
IL300870A (en) 2023-04-01
RU2711638C2 (ru) 2020-01-17
US20150182524A1 (en) 2015-07-02
US9801875B2 (en) 2017-10-31
EP3076971A1 (en) 2016-10-12
US20190314363A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
IL273205A (en) Preparations and methods
LT3076971T (lt) Kompozicijos ir būdai, skirti sumažinti didžiąsias širdies ir kraujagyslių komplikacijas
GB2533892B (en) Compositions and methods
LT3021852T (lt) Neuroaktyvūs steroidai, jų kompozicijos ir panaudojimas
SMT201900635T1 (it) Composizioni e metodi di attivazione della segnalazione dipendente dallo "stimolatore di geni interferone"
EP2951283A4 (en) Compositions and methods
BR112015028459A2 (pt) composições e comestíveis
LT2943078T (lt) Maisto medžiagų gamybos būdas ir sudėtis
GB201308072D0 (en) Compositions and methods
EP2797556A4 (en) ANCHORED CARDIOVASCULAR FLAP
EP2889350A4 (en) ADHESIVE COMPOSITION
EP3071215A4 (en) Compositions and methods for treating pulmonary hypertension
DK3027750T3 (da) Biokatalytisk sammensætning
GB201305414D0 (en) Method and composition
GB201301702D0 (en) Exhaust cone
EP3006525A4 (en) ASPHALT-URETHANE COMPOSITION
GB201319540D0 (en) Composition
GB201305813D0 (en) Compositions and methods
SG11201507608PA (en) Toxoid, compositions and related methods
DK3130236T3 (da) Ernæringssammensætning
IL239680B (en) Preparations and methods for polynucleotide transfection
SG11201602845UA (en) Pyrometer background elimination
PL3019024T3 (pl) Kompozycje i sposoby do zwiększania wydolności podczas wysiłku fizycznego
EP3065550A4 (en) Methods and compositions for treating sepsis
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF